Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
Sponsor: Eli Lilly and Company
Summary
The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Official title: A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4064912 in Healthy Participants and Participants With Overweight or Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
144
Start Date
2025-08-28
Completion Date
2026-11
Last Updated
2026-03-03
Healthy Volunteers
Yes
Conditions
Interventions
LY4064912
Administered SC
LY4064912
Administered IV
Placebo
Administered SC
Placebo
Administered IV
Locations (3)
Collaborative Neuroscience Network - CNS
Los Alamitos, California, United States
ICON Early Phase Services
San Antonio, Texas, United States
Lilly Centre for Clinical Pharmacology
Singapore, Singapore